1-{4-[(E)-Phenyldiazenyl]phenyl}-1H-pyrrole-2,5-dione | 136733-06-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: 1-{4-[(E)-Phenyldiazenyl]phenyl}-1H-pyrrole-2,5-dione
• 英文别名: (E)-1-(4-(phenyldiazenyl)phenyl)-1H-pyrrole-2,5-dione；(E)-4-phenylazomaleinanil；4-(N-maleimido)azobenzene；N-(4-azobenzene)maleimide；4-(N-maleimido)azobenze；4-phenylazomaleanil；4-PAM
• CAS: 136733-06-7
• 化学式: C₁₆H₁₁N₃O₂
• 分子量: 277.282
• InChiKey: DVNPYLMPVFDKGZ-ISLYRVAYSA-N

物化性质

• 熔点：
  160-161 °C
• 沸点：
  475.1±28.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.53
• 重原子数：
  21.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.1
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-{4-[(E)-Phenyldiazenyl]phenyl}-1H-pyrrole-2,5-dione 以 aq. buffer 为溶剂， 生成 1H-Pyrrole-2,5-dione, 1-[4-[(1Z)-phenylazo]phenyl]-
  参考文献：
  名称：

  Azobenzene switch with a long-lived cis-state to photocontrol the enzyme activity of a histone deacetylase-like amidohydrolase

  摘要：

  利用外部刺激，如光，对酶的控制可以高度精确地调节定义化学反应的时间和空间。在这项工作中，我们研究并表征了一种可逆光控制的细菌组蛋白去乙酰化酶类似物（HDAH），该酶来自于Bordetella/Alcaligenes菌株FB188，具有在生物技术和生物医学应用中控制广谱基质去乙酰化反应的巨大潜力。我们开发了几种具有单个表面可接近活性位点的半胱氨酸变体，并通过单功能偶氮苯基光开关[4-苯基偶氮马来酰胺（4-PAM）]进行共价修饰。三种HDAH变体（M30C、S20C和M150C）的酶活性被证明可以通过光来控制。与未结合的4-PAM相比，偶联到HDAH上的偶氮苯的热性顺式-反式松弛最多可减缓50倍，从而允许使用光脉冲开关而不是继续照射以维持共价连接的4-PAM的热力学不稳定的顺式状态。

  DOI：

  10.1515/hsz-2013-0246
• 作为产物：
  描述：

  N-(4-phenylazo-phenyl)-maleamic acid 在 sodium acetate 、 乙酸酐 作用下， 反应 4.0h， 生成 1-{4-[(E)-Phenyldiazenyl]phenyl}-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  摘要：

  We have grown layered assemblies of poly[4-(N-maleimido) azobenzene-co-diisopropyl (2-vinyloxy)-ethylphosphonate], (poly( MAB-VEP)), where interlayer connections are made using zirconium bisphosphonate (ZP) ionic complexation chemistry. The linear optical response of the azobenzene chromophore side group shows constant layer density but a layer-dependent ratio of trans-to-cis isomers. Optical null ellipsometry data show a constant average layer thickness despite the change in conformer ratio. The change in conformer ratio with the growth of multiple polymer layers results from the steric constraints imposed on the polymer side groups by the formation of the ZP interlayer linkage. The driving force for metal ion complexation is greater than the isomerization barrier of S-0 azobenzene. Once the layers are formed, the side-groups do not exhibit any changes in conformer ratio, even when exposed to UV for a prolonged period.

  DOI：

  10.1039/b103251h

文献信息

• Highly efficient photocontrol of mitotic kinesin Eg5 ATPase activity using a novel photochromic compound composed of two azobenzene derivatives
  作者：Kei Sadakane、Islam M D Alrazi、Shinsaku Maruta

  DOI：10.1093/jb/mvy051

  日期：2018.10.1

  physiological role in cell division. Several small-molecule inhibitors of Eg5 are the focus of cancer therapies. Azobenzene is a photochromic compound exhibiting cis-trans isomerization upon ultraviolet (UV) and visible (VIS) light irradiation. Photochromic compounds of azobenzene derivatives, mimicking Eg5-specific inhibitors of STLC, indicated photoreversible inhibitory effects on Eg5 ATPase activity;

  有丝分裂驱动蛋白Eg5在细胞分裂中起着重要的生理作用。Eg5的几种小分子抑制剂是癌症治疗的重点。偶氮苯是一种光致变色化合物，在紫外线（UV）和可见光（VIS）照射下表现出顺反异构化。模仿STLC的Eg5特异性抑制剂的偶氮苯衍生物的光致变色化合物显示出对Eg5 ATPase活性的光可逆抑制作用。然而，光可逆转换效率并不显着。这项研究提出了一种新型的合成的光致变色Eg5抑制剂2，3-双[（2,5-二氧-1--1- 4-[（E）-2-苯基重氮-1-基]苯基}吡咯烷-3-基）硫烷基]丁二酸（BDPSB），由两个偶氮苯组成。BDPSB在UV和VIS光照射下表现出顺反异构化。BDPSB的反式显着抑制了Eg5的微管依赖性ATPase活性，IC50为74μM。Cis BDPSB对微管依赖的ATPase活性显示出较弱的影响。结果表明，新型的光致变色Eg5抑制剂BDPSB具有高效的光开关性能，在VIS和UV光照射下显示出“
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DRUG ADDICTION<br/>[FR] MÉTHODES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE LA TOXICOMANIE
  申请人：UNIV NICE SOPHIA ANTIPOLIS

  公开号：WO2016026978A1

  公开（公告）日：2016-02-25

  The present invention relates to methods and pharmaceutical compositions for treating drug addiction, preferably alcoholism, ecstasy addiction or cocaine addiction, in a subject in need thereof. In particular, the present invention relates to a method for treating drug addiction in a subject in need thereof comprising administering the subject with a TREK agonist, particularly a TREK1 and/or TREK2 agonist.

  本发明涉及用于治疗药物成瘾的方法和药物组合物，优选用于治疗酒精中毒、摇头丸成瘾或可卡因成瘾的主体。具体来说，本发明涉及一种治疗药物成瘾的方法，包括向需要的主体施用TREK激动剂，特别是TREK1和/或TREK2激动剂。
• Copolymers containing fluorine, method for the production and use thereof
  申请人：——

  公开号：US20040242822A1

  公开（公告）日：2004-12-02

  The present invention relates to relates to copolymers containing fluorine, aqueous compositions containing said copolymers, and the use of said copolymers and compositions for surface treatment.

  本发明涉及含氟共聚物，含有该共聚物的水性组合物以及使用该共聚物和组合物进行表面处理的方法。
• Methods for coating surfaces with antimicrobial agents
  申请人：The Board of Regents of the University of Texas System

  公开号：US10589003B2

  公开（公告）日：2020-03-17

  Disclosed are methods for coating or impregnating a surface with an antimicrobial agent that involve contacting the surface with a composition that includes an antimicrobial agent and a solvent, and curing the surface by applying heat. Also disclosed are methods for reducing the risk of development or progression of an infection in a subject in need of a medical device, that involve coating or impregnating a surface of the medical device with an antimicrobial agent and then curing the surface by applying heat, wherein the risk of development or progression of an infection is reduced.

  本发明公开了用抗菌剂涂覆或浸渍表面的方法，包括用包括抗菌剂和溶剂的组合物接触表面，并通过加热固化表面。还公开了降低需要使用医疗器械的受试者发生或恶化感染风险的方法，包括用抗菌剂涂覆或浸渍医疗器械表面，然后通过加热固化表面，从而降低发生或恶化感染的风险。
• Method for fabricating two-dimensional protein crystals
  申请人：The Regents of the University of California

  公开号：US11286277B2

  公开（公告）日：2022-03-29

  Polypeptide assemblies and building blocks and methods for making them are provided.

  提供了多肽组件和构建模块以及制造它们的方法。

表征谱图